A

Amgen

Makes biotech medicines for serious illnesses

Regional Account Manager - Uplizna, Rare Disease

Full-TimeUpdated on 10/24/2026
$185.9k - $270.8k/yr
Mid
Bachelor's, Master's, PhD, Associate's
Houston, TX, USA+2 moreMore locations: Austin, TX, USA | San Antonio, TX, USA
In PersonField-based role covering the listed Texas locations; requires approximately 20–30% travel, including some overnight and weekend commitments.
Sales & Account ManagementAccount Management

About the job

Requirements
  • A doctorate degree and 2 years of collective account management, sales, and commercial experience; or a master's degree and 6 years; or a bachelor's degree and 8 years; or an associate degree and 10 years.
  • Approximately 20–30% travel, including some overnight and weekend commitments.
Responsibilities
  • Represent company products to top-tier physicians, healthcare professionals, and affiliated institutional systems; establish product sales and perform strategic account management, including disease information and education for medical professionals and affiliates involved in treatment decisions.
  • Achieve quarterly sales objectives by promoting patient-centered disease and product education to healthcare professionals and systems, while adhering to corporate compliance guidelines.
  • Implement marketing-plan goals through execution of a strategic account business plan; allocate resources based on leading and lagging indicators and achieve brand outcomes.
  • Work in a matrix environment with specialty account managers, thought leader liaisons, case managers, medical affairs, patient access teams, and other partners; share insights, adjust strategies, seek feedback, and improve account performance.
  • Use available resources and programs, including peer-to-peer education and cross-functional partners, to address identified knowledge gaps.
  • Navigate the healthcare landscape, including academic institutions, integrated delivery networks, accountable care organizations, and community hospital systems; identify opportunities, conduct strategic account conversations, and communicate across organizational levels.
  • Establish productive business relationships with key local, regional, and national key opinion leaders within the territory and assigned therapeutic areas.
  • Promote and support product use within target institutions, often working with medical and scientific teams.
  • Understand and navigate market access, including government regulations, reimbursement models, and payer trends.
  • Identify and pursue institutional-channel business opportunities that positively affect institutions and their surrounding referral geographies.
  • Monitor and analyze sales data, market trends, and competitive activity to identify areas for improvement and growth.
  • Maintain in-depth disease, therapeutic, clinical, and scientific knowledge; seek current research and developments and share approved product messages with healthcare providers.
  • Use a consultative, technically oriented selling approach to address the needs of healthcare professionals treating neuro-immunologic patients; anticipate questions and align clinical data with strategic goals to influence treatment decisions.
  • Adhere to compliance and corporate policies, including appropriate documentation and reporting.
Desired Qualifications
  • At least 3 years of in-office injection or infusion sales experience selling a medical-benefit product that requires extensive coordination with patient access services.
  • Experience operating in a matrix selling environment and collaborating with patient services, market access, medical affairs, and reimbursement, with a significant focus on patient centricity.
  • Market development or deep profiling experience in rare, unmet spaces.
  • Success educating healthcare professionals about complex diseases diagnosed through clinical observation involving diverse patient profiles that do not always lend themselves to simple segmentation diagnosis.
  • A documented track record of consistent, exceptional performance.
  • Ability to work independently in a fast-paced, challenging work environment.
  • Strong written and verbal communication skills.
  • Strong organizational, analytical, and computer skills.
  • Proficiency in Microsoft Office.
  • Professional and proactive demeanor.
  • Strong interpersonal skills.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.